Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

@article{Kyle2003CriteriaFT,
  title={Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group},
  author={R. Kyle and J. Child and K. Anderson and B. Barlogie and R. Bataille and W. Bensinger and J. Blad{\'e} and M. Boccadoro and W. Dalton and M. Dimopoulos and B. Djulbegovic and M. Drayson and B. Durie and T. Facon and R. Fonseca and G. Gahrton and P. Greipp and Jean‐Luc Harousseau and D. Harrington and M. Hussein and D. Joshua and H. Ludwig and G. Morgan and M. Oken and R. Powles and P. Richardson and David Roodman and J. S. Miguel and K. Shimizu and C. Shustik and B. Sirohi and P. Sonneveld and G. Tricot and I. Turesson and B. Ness and D. Vesole and D. Weber and J. Westin and K. Wheatley},
  journal={British Journal of Haematology},
  year={2003},
  volume={121}
}
  • R. Kyle, J. Child, +36 authors K. Wheatley
  • Published 2003
  • Medicine
  • British Journal of Haematology
  • Summary. The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Background: - Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and… Expand
    ConditionsMultiple Myeloma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    Background: - Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection. MM is nearly always… Expand
    ConditionsMonoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM. The second one is to… Expand
    ConditionsMultiple Myeloma
    InterventionProcedure
    INTERVENTIONAL CLINICAL TRIAL
    Background: - Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a… Expand
    ConditionsMonoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
    InterventionDrug, Other
    Myeloma and MGUS

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 36 REFERENCES
    Monoclonal gammopathy of undetermined significance.
    176
    Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.
    369
    A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    1128
    "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.
    236